35
E., Mclaughlin P. et al. Results of recent salvage chemotherapy regimens
for lymphoma and Hodgkin’s disease // Seminars in Hematology. – 1988.
– Vol. 25. – P. 47-50., 5, 11, 28, 29 \\\ Coiffier B., Lepage E., Briere et
al. CHOP Chemotherapy plus Rituximab compared with CHOP alone
in elderly patients with diffuse large-B-cell lymphoma // NEJM. – 2002.
– Vol. 346 – P. 235-242.\\\ Pfreundschuh M., Trumper L., Kloess M. et
al. Two-weekly or 3-weekly CHOP chemotherapy with or without
etoposide for the treatment of young patients with good prognosis (normal
LDH) aggressive lymphomas: results of the NHL, B1 trial of the
DSHNHL // Blood. – 2004. – Vol. 104. – P. 626-633.). Ïðîâåäåííàÿ
òåðàïèÿ ñîïðîâîæäåíèÿ â ñîñòîÿíèè ïðîôèëàêòèðîâàòü ìíîãèå èç
âûøåóêàçàííûõ îñëîæíåíèé è íåäîïóñòèòü íàèáîëåå ãðîçíîãî èç
íèõ – ìèåëîñóïðåññèè (Trillet A, Lenoir V., Green J., Manegold C. et
al. Recombinant granulocyte colony stimulating factor reduces the
infectious complications of cytotoxic chemotherapy // Europ. J. Cancer.
– 1993. – Vol. 29A. – P. 319-322.).
Öåëüþ íàøåãî èññëåäîâàíèÿ áûëî èçó÷åíèÿ êîìïëåêñíîãî
ïðåïàðàòà (Essential C-curity «Santegra», USA) áèîôëàâîíîèäîâ,
äèåòè÷åñêèõ èíäîëîâ, âèòàìèíà Ñ (ïîëó÷åííîãî èç ðàçëè÷íûõ
èñòî÷íèêîâ) è ðàñòèòåëüíîãî öèíêà, âûäåëåííîãî ïî
ïàòåíòèðîâàííûì òåõíîëîãèÿì èç ëèñòüåâ ðàñòåíèÿ Brassica juncea
(èíäèéñêîé ãîð÷èöû). Ñîñòàâ ïðåïàðàòà: ôèòîöèíê, âèòàìèí Ñ
(èç àñêîðáèíîâîé êèñëîòû, àñêîðáàòà êàëüöèÿ,
àñêîðáèëïàëüìèòàòà, ïëîäîâ àöåðîëû, ÿãîä ìîææåâåëüíèêà,
ïëîäîâ øèïîâíèêà), êîìïëåêñ ãåñïåðèäèíà, êîìïëåêñ öèòðóñîâûõ
áèîôëàâîíîèäîâ, ðóòèí, äèåòè÷åñêèå èíäîëû. Ïî äàííûì
ëèòåðàòóðû (McCausland, ph. d., USA, 1996), êàæäûé êîíêðåòíûé
èíãðåäèåíò íàñòîÿùåãî êîìïëåêñíîãî ïðåïàðàòà ñïîñîáñòâóåò
ñòàáèëèçàöèè ôóíêöèé ñåðäå÷íî-ñîñóäèñòîé ñèñòåìû, îêàçûâàåò
ïðîòåêòîðíîå âëèÿíèå íà ñîñòîÿíèå èììóííîé ñèñòåìû, ÿâëÿåòñÿ
ìîùíûì àíòèîêñèäàíòîì, ïðåäîõðàíÿþùèì îò ïîâðåæäåíèé,
íàíîñèìûõ ñâîáîäíûìè ðàäèêàëàìè, ñïîñîáñòâóåò óìåíüøåíèþ
îáðàçîâàíèÿ îïóõîëåâûõ êëåòîê. Îñîáîå âíèìàíèå â íåäàâíèõ
èññëåäîâàíèÿõ óäåëåíî äèåòè÷åñêèì èíäîëàì, êîòîðûå
ïîääåðæèâàþò ãîðìîíàëüíûé áàëàíñ â îðãàíèçìå, óêðåïëÿþò
èììóííóþ è ýíäîêðèííóþ ñèñòåìû, ñíèæàþò ðèñê çàáîëåâàíèÿ
ðàêîì ìîëî÷íîé æåëåçû è ïðÿìîé êèøêè.